Microbiotix, Inc.
CAGE Code: 465F8
NCAGE Code: 465F8
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 158864715
Summary
Microbiotix, Inc. is an Active Commercial Supplier with the Cage Code 465F8 and is tracked by Dun & Bradstreet under DUNS Number 158864715..
Address
1 Innovation Dr Ste 120C
Worcester MA 01605-4307
United States
Points of Contact
Related Information
People who viewed this 'CAGE Code' also viewed...
T M Electronics Inc Standard Lock Washer & Mfg Co Inc International Ceramic Engineering Star Janitorial And Maintenance Inc Elangen, Inc. Northeast Janitorial Services, Inc Russell Marine Instant New Homes Inc Jefferson Wire And Cable Corp Pacific Scientific Services Inc Delve-Explore Services Llc Dara Koutal Endeavors Inc Powders On Demand Llc Benk Logistics L.C R J C Sales Wright Machine Corp Arter Grinding Machine Co A B Mfg Co Eti Industries Inc Jcl Div 2Gether We Eat Inc
Frequently Asked Questions (FAQ) for CAGE 465F8
- What is CAGE Code 465F8?
- 465F8 is the unique identifier used by NATO Organizations to reference the physical entity known as Microbiotix, Inc. located at 1 Innovation Dr Ste 120C, Worcester MA 01605-4307, United States.
- Who is CAGE Code 465F8?
- 465F8 refers to Microbiotix, Inc. located at 1 Innovation Dr Ste 120C, Worcester MA 01605-4307, United States.
- Where is CAGE Code 465F8 Located?
- CAGE Code 465F8 is located in Worcester, MA, USA.
Contracting History for CAGE 465F8 Most Recent 25 Records
- 75N93023C00001
- To Develop The Ppz Series Of Small Molecule Pan-Filovirus Entry Inhibitors Through Lead Optimization, Selection Of A Preclinical Candidate, And Ind-Enabling Preclinical Studies.
- 31 Oct 2022
- To Develop The Ppz Series Of Small Molecule Pan-Filovirus Entry Inhibitors Through Lead Optimization, Selection Of A Preclinical Candidate, And Ind-Enabling Preclinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,069,416.00
- Department Of Health And Human Services (Hhs)
- 75N93023C00001
- To Develop The Ppz Series Of Small Molecule Pan-Filovirus Entry Inhibitors Through Lead Optimization, Selection Of A Preclinical Candidate, And Ind-Enabling Preclinical Studies.
- 26 Sep 2023
- To Develop The Ppz Series Of Small Molecule Pan-Filovirus Entry Inhibitors Through Lead Optimization, Selection Of A Preclinical Candidate, And Ind-Enabling Preclinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,069,416.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 7 Dec 2021
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $904,896.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 3 Mar 2022
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,204,539.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 15 May 2023
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,035,419.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 3 Nov 2022
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,204,539.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 15 Nov 2021
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $904,896.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- Eo14042 - To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 14 Oct 2021
- Eo14042 - To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,204,539.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 18 Apr 2023
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,035,419.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00019
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- 12 Dec 2022
- To Develop Phenoxyacetamide T3ss Inhibitors As Adjunctive Agents To Antibacterial Therapy For Mdr P. Aeruginosa Infections.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,204,539.00
- Department Of Health And Human Services (Hhs)
- HDTRA118C0001
- Develop Novel And Innovative Small Molecule Therapeutics To Treat (Post-Exposure Therapeutic) Infections By Both Filovirus Family Members (Ebola Viruses And Marburg Viruses).
- 11 May 2021
- Develop Novel And Innovative Small Molecule Therapeutics To Treat (Post-Exposure Therapeutic) Infections By Both Filovirus Family Members (Ebola Viruses And Marburg Viruses).
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $2,594,319.91
- Department Of Defense (Dod)
- HDTRA118C0001
- Develop Novel And Innovative Small Molecule Therapeutics To Treat (Post-Exposure Therapeutic) Infections By Both Filovirus Family Members (Ebola Viruses And Marburg Viruses).
- 9 Nov 2021
- Develop Novel And Innovative Small Molecule Therapeutics To Treat (Post-Exposure Therapeutic) Infections By Both Filovirus Family Members (Ebola Viruses And Marburg Viruses).
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $2,594,319.91
- Department Of Defense (Dod)